BRCA+ ovarian cancer: heavily treated patients retain chemosensitivity in Spanish study

  • Rodriguez-Freixinos V & et al.
  • Gynecol Oncol
  • 12 Dec 2018

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Heavily pretreated patients with BRCA1/2-mutated ovarian cancer showed sensitivity for chemotherapy (CT), even in platinum-resistant setting.
  • Primary platinum-free interval (PFI) >12 months, platinum-based CT (platinum-CT), and PARP inhibitors (PARPi) were associated with improved prognosis.

Why this matters

  • Platinum resistance status based on

Study design

  • 135 heavily pretreated patients with BRCA1/2+ ovarian cancer received CT.
  • Patients were classified according to PFI after last platinum-CT (platinum-resistant,
  • Median CT lines: 2.
  • Funding: Vall d'Hebron Institute of Oncology.

Key results

  • Median follow-up, 5.8 years.
  • 6-year OS rate was similar between BRCA1 and BRCA2 mutation carriers (P=.98).
  • Median time to progression (TTP) beyond second-line therapy was 10.2 (95% CI, 8.4-11.9) months in overall and 6.1 (95% CI, 4.5-7.7) months in platinum-resistant patients.
  • Compared with non-platinum-CT (4.9 months), TTP significantly improved with platinum-CT+PARPi, platinum-CT, or PARPi (17.1, 12.6, 12.4 months, respectively; Pall<.001 in platinum-sensitive patients.>
  • In platinum-resistant patients, TTP was not statistically different between treatments.
  • Primary PFI >12 months (HR, 0.32; P=.01), platinum-CT (HR, 0.3; P<.001 and parpi p=".04)" were associated with improved outcomes.>

Limitations

  • Retrospective design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit